News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by NextCure
< Previous
1
2
Next >
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
Today 8:05 EDT
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
March 31, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
March 05, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update
January 23, 2026
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
November 20, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
November 17, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
November 12, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
November 05, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 16, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 04, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
August 07, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta
July 24, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
June 16, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
May 29, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
May 01, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference
April 04, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
March 06, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
January 10, 2025
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Announces Acceptance of IND Application for LNCB74
December 10, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
November 26, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
November 19, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
November 07, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
November 05, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
October 04, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
September 16, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
August 01, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 20, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
May 30, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
May 02, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
April 24, 2024
From
NextCure
Via
GlobeNewswire
Tickers
NXTC
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.